Corporate profile

Geron is working to change the course of hematologic malignancies

Geron is a late-stage biopharmaceutical company with a mission to extend and enhance the lives of patients living with hematologic malignancies. Our first-in-class telomerase inhibitor, imetelstat, has demonstrated strong evidence of disease modification in Phase 2 trials.

Geron is focused on the development and potential commercialization of imetelstat and currently has two Phase 3 clinical trials ongoing: IMerge in lower risk myelodysplastic syndromes (LR MDS) and IMpactMF in relapsed/refractory myelofibrosis (MF). These indications represent potential multi-billion-dollar market opportunities. We have an experienced and knowledgeable management team and employee base to execute and deliver on our mission.

Press releases


Upcoming events



Stipulation of Settlement and Notice of Pendency of Settlement of Derivative Litigation

Corporate presentation

Stock information

Contact information

Geron investor relations